{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:13:10Z","timestamp":1790701990692,"version":"4.1.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The conclusions of pairwise meta-analyses of interventions for actinic keratosis (AK) are limited due to the lack of direct comparison between some interventions. Consequently, we performed a network meta-analysis for eight treatments [5-aminolaevulinic acid (ALA)-photodynamic therapy (PDT), cryotherapy, diclofenac 3% in 2\u00b75% hyaluronic acid (DCF\/HA), 5-fluorouracil (5-FU) 0\u00b75% or 5\u00b70%, imiquimod (IMI) 5%, ingenol mebutate (IMB) 0\u00b7015\u20130\u00b705%, methyl aminolaevulinate (MAL)-PDT and placebo\/vehicle (including placebo-PDT)] to determine their relative efficacies. As part of a prior Cochrane systematic review, different databases and grey literature were searched for randomized controlled trials up to April 2012. The inclusion criteria were parallel-group studies with nonimmunosuppressed participants: (i) reporting \u2018participant complete clearance\u2019 and (ii) comparing at least two of the interventions. Thirty-two publications met the criteria and they included the following number of individual or pooled studies (n) and total number of participants (N) for the different interventions: 5-FU 0\u00b75% (n =4, N =169), 5-FU 5\u00b70% (n =2, N =44), ALA-PDT (n =6, N =739), cryotherapy (n =2, N =174), DCF\/HA (n =5, N =299), IMI (n =14, N =1411), IMB (n =3, N =560), MAL-PDT (n =7, N =557) and placebo (n =32, N =2520). Network analyses using a random-effects Bayesian model were carried out with the software ADDIS v1.16.1. The interventions were ranked as follows based on calculated probabilities and odd ratios: 5-FU &amp;gt; ALA-PDT \u2248 IMI \u2248 IMB \u2248 MAL-PDT &amp;gt; cryotherapy &amp;gt; DCF\/HA &amp;gt; placebo. This efficacy ranking was obtained based on the current available data on \u2018participant complete clearance\u2019 from randomized controlled trials and the analysis model used. However, several other factors should also be considered when prescribing a treatment for AK.<\/jats:p>","DOI":"10.1111\/bjd.12343","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T08:54:35Z","timestamp":1364547275000},"page":"250-259","source":"Crossref","is-referenced-by-count":99,"title":["Network meta-analysis of the outcome \u2018participant complete clearance\u2019 in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review"],"prefix":"10.1093","volume":"169","author":[{"given":"A.K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paquet","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc. London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2023083115545934600_bjd12343-bib-0001","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0190-9622(97)70265-2","article-title":"Actinic keratoses","volume":"36","author":"Callen","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0002","first-page":"201","article-title":"Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications","volume":"87","author":"Feldman","year":"2011","journal-title":"Cutis"},{"key":"2023083115545934600_bjd12343-bib-0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2007.08268.x","article-title":"Management of field change in actinic keratosis","volume":"157","author":"Vatve","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0004","volume-title":"ADDIS: an automated way to do network meta-analysis","author":"Zhao"},{"key":"2023083115545934600_bjd12343-bib-0005","volume-title":"ADDIS: a decision support system for evidence-based medicine","author":"van Valkenhoef"},{"key":"2023083115545934600_bjd12343-bib-0006","first-page":"CD004415","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2023083115545934600_bjd12343-bib-0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1440-0960.1997.tb01693.x","article-title":"Topical diclofenac\/hyaluronic acid gel in the treatment of solar keratoses","volume":"38","author":"McEwan","year":"1997","journal-title":"Australas J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0010","volume-title":"Solaraze gel: diclofenac sodium 3% \u2013 package insert","author":"PharmaDerm"},{"key":"2023083115545934600_bjd12343-bib-0011","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis","volume":"70","author":"Jorizzo","year":"2002","journal-title":"Cutis"},{"key":"2023083115545934600_bjd12343-bib-0012","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0013","first-page":"22","article-title":"Effective treatment of actinic keratosis with 0\u00b75% fluorouracil cream for 1, 2, or 4 weeks","volume":"70","author":"Weiss","year":"2002","journal-title":"Cutis"},{"key":"2023083115545934600_bjd12343-bib-0014","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","article-title":"Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial","volume":"44","author":"Chen","year":"2003","journal-title":"Australas J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1067\/mjd.2003.49","article-title":"Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial","volume":"48","author":"Pariser","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0017","first-page":"629","article-title":"Short incubation PDT versus 5-FU in treating actinic keratoses","volume":"2","author":"Smith","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0018","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","article-title":"Effect of a 1-week treatment with 0\u00b75% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial","volume":"140","author":"Jorizzo","year":"2004","journal-title":"Arch Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0019","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0020","volume-title":"Metvixia cream 16\u00b78%, product insert","author":"Photocure"},{"key":"2023083115545934600_bjd12343-bib-0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.140.1.41","article-title":"Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials","volume":"140","author":"Piacquadio","year":"2004","journal-title":"Arch Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0022","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0024","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2133.2005.06932.x","article-title":"Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial","volume":"154","author":"Ooi","year":"2006","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head","volume":"157","author":"Alomar","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"2023083115545934600_bjd12343-bib-0027","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0028","first-page":"144","article-title":"Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0029","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2008.05.031","article-title":"Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study","volume":"59","author":"Pariser","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0\u00b7025% and 0\u00b705% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0031","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0032","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2009.09040.x","article-title":"Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies","volume":"160","author":"Hauschild","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0033","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1524-4725.2009.01096.x","article-title":"Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study","volume":"35","author":"Szeimies","year":"2009","journal-title":"Dermatol Surg"},{"key":"2023083115545934600_bjd12343-bib-0034","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study","volume":"163","author":"Szeimies","year":"2010","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0036","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"2023083115545934600_bjd12343-bib-0037","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.jaad.2011.11.933","article-title":"A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes","volume":"66","author":"Serra-Guill\u00e9n","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0038","volume-title":"A therapeutic equivalence study of two imiquimod cream 5% treatments for patients with actinic keratosis","author":"ClinicalTrials.gov. NCT00828568"},{"key":"2023083115545934600_bjd12343-bib-0039","first-page":"1432","article-title":"A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes","volume":"10","author":"Foley","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14370","article-title":"A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin","volume":"14","author":"Fayter","year":"2010","journal-title":"Health Technol Assess"},{"key":"2023083115545934600_bjd12343-bib-0041","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0042","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000329025","article-title":"Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis","volume":"222","author":"Gholam","year":"2011","journal-title":"Dermatology"},{"key":"2023083115545934600_bjd12343-bib-0043","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1039\/b823378k","article-title":"Topical photodynamic therapy with porphyrin precursors \u2013 assessment of treatment-associated pain in a retrospective study","volume":"8","author":"Steinbauer","year":"2009","journal-title":"Photochem Photobiol Sci"},{"key":"2023083115545934600_bjd12343-bib-0044","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/00015555-1223","article-title":"Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid","volume":"92","author":"Ga\u00e1l","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2023083115545934600_bjd12343-bib-0045","first-page":"241","article-title":"What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents","volume":"89","author":"Berman","year":"2012","journal-title":"Cutis"},{"key":"2023083115545934600_bjd12343-bib-0046","first-page":"23","article-title":"Pharmacoeconomic analysis of the treatment of multiple actinic keratoses","volume":"7","author":"Gold","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0047","first-page":"30","article-title":"The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation","volume":"70","author":"Gupta","year":"2002","journal-title":"Cutis"},{"key":"2023083115545934600_bjd12343-bib-0048","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09546630902887211","article-title":"An economic evaluation of topical treatments for actinic keratosis","volume":"20","author":"Muston","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"2023083115545934600_bjd12343-bib-0049","first-page":"573","article-title":"Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system","volume":"145","author":"Colombo","year":"2010","journal-title":"G Ital Dermatol Venereol"},{"key":"2023083115545934600_bjd12343-bib-0050","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.2006.07483.x","article-title":"Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma","volume":"155","author":"Caekelbergh","year":"2006","journal-title":"Br J Dermatol"},{"key":"2023083115545934600_bjd12343-bib-0051","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","article-title":"Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses","volume":"28","author":"Wilson","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"2023083115545934600_bjd12343-bib-0052","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mjd.2002.119649","article-title":"Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study","volume":"47","author":"Szeimies","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/169\/2\/250\/51316956\/bjd0250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/169\/2\/250\/51316956\/bjd0250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:15:42Z","timestamp":1693498542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/169\/2\/250\/6615141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12343","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8,1]]},"published":{"date-parts":[[2013,8,1]]}}}